Literature DB >> 33074657

An Engineered T Cell Receptor Variant Realizes the Limits of Functional Binding Modes.

Nishant K Singh1, Jesus A Alonso1, Daniel T Harris2, Scott D Anderson2, Jiaqi Ma1, Lance M Hellman1, Aaron M Rosenberg1, Elizabeth M Kolawole3, Brian D Evavold3, David M Kranz2, Brian M Baker1.   

Abstract

T cell receptors (TCRs) orchestrate cellular immunity by recognizing peptides presented by a range of major histocompatibility complex (MHC) proteins. Naturally occurring TCRs bind the composite peptide/MHC surface, recognizing peptides that are structurally and chemically compatible with the TCR binding site. Here we describe a molecularly evolved TCR variant that binds the human class I MHC protein HLA-A2 independent of the bound peptide, achieved by a drastic perturbation of the TCR binding geometry that places the molecule far from the peptide binding groove. This unique geometry is unsupportive of normal T cell signaling. A substantial divergence between affinity measurements in solution and in two dimensions between proximal cell membranes leads us to attribute the lack of signaling to steric hindrance that limits binding in the confines of a cell-cell interface. Our results provide an example of how receptor binding geometry can impact T cell function and provide further support for the view that germline-encoded residues in TCR binding loops evolved to drive productive TCR recognition and signaling.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33074657      PMCID: PMC7642186          DOI: 10.1021/acs.biochem.0c00689

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  60 in total

1.  Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.

Authors:  V Rubio-Godoy; V Dutoit; D Rimoldi; D Lienard; F Lejeune; D Speiser; P Guillaume; J C Cerottini; P Romero; D Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.

Authors:  Oleg Y Borbulevych; Priscilla Do; Brian M Baker
Journal:  Mol Immunol       Date:  2010-07-08       Impact factor: 4.407

3.  Version 1.2 of the Crystallography and NMR system.

Authors:  Axel T Brunger
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 4.  T cell antigen receptor recognition of antigen-presenting molecules.

Authors:  Jamie Rossjohn; Stephanie Gras; John J Miles; Stephen J Turner; Dale I Godfrey; James McCluskey
Journal:  Annu Rev Immunol       Date:  2014-12-10       Impact factor: 28.527

5.  Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Authors:  Lance M Hellman; Kendra C Foley; Nishant K Singh; Jesus A Alonso; Timothy P Riley; Jason R Devlin; Cory M Ayres; Grant L J Keller; Yuting Zhang; Craig W Vander Kooi; Michael I Nishimura; Brian M Baker
Journal:  Mol Ther       Date:  2018-12-14       Impact factor: 11.454

6.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

7.  T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex.

Authors:  Jarrett J Adams; Samanthi Narayanan; Baoyu Liu; Michael E Birnbaum; Andrew C Kruse; Natalie A Bowerman; Wei Chen; Aron M Levin; Janet M Connolly; Cheng Zhu; David M Kranz; K Christopher Garcia
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

8.  Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode.

Authors:  David K Cole; Malkit Sami; Daniel R Scott; Pierre J Rizkallah; Oleg Y Borbulevych; Penio T Todorov; Ruth K Moysey; Bent K Jakobsen; Jonathan M Boulter; Brian M Baker
Journal:  Front Immunol       Date:  2013-06-26       Impact factor: 7.561

Review 9.  T cells and their eons-old obsession with MHC.

Authors:  Lei Yin; James Scott-Browne; John W Kappler; Laurent Gapin; Philippa Marrack
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

10.  Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.

Authors:  Jennifer D Stone; David M Kranz
Journal:  Front Immunol       Date:  2013-08-21       Impact factor: 7.561

View more
  3 in total

1.  Atypical sideways recognition of CD1a by autoreactive γδ T cell receptors.

Authors:  Marcin Wegrecki; Tonatiuh A Ocampo; Sachith D Gunasinghe; Anouk von Borstel; Shin Yi Tin; Josephine F Reijneveld; Thinh-Phat Cao; Benjamin S Gully; Jérôme Le Nours; D Branch Moody; Ildiko Van Rhijn; Jamie Rossjohn
Journal:  Nat Commun       Date:  2022-07-05       Impact factor: 17.694

2.  Dynamic allostery controls the peptide sensitivity of the Ly49C natural killer receptor.

Authors:  Jiaqi Ma; Cory M Ayres; Lance M Hellman; Jason R Devlin; Brian M Baker
Journal:  J Biol Chem       Date:  2021-04-20       Impact factor: 5.157

3.  Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.

Authors:  Smita S Chandran; Jiaqi Ma; Martin G Klatt; Friederike Dündar; Chaitanya Bandlamudi; Pedram Razavi; Hannah Y Wen; Britta Weigelt; Paul Zumbo; Si Ning Fu; Lauren B Banks; Fei Yi; Enric Vercher; Inaki Etxeberria; Watchain D Bestman; Arnaud Da Cruz Paula; Ilinca S Aricescu; Alexander Drilon; Doron Betel; David A Scheinberg; Brian M Baker; Christopher A Klebanoff
Journal:  Nat Med       Date:  2022-04-28       Impact factor: 87.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.